Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hanyue Ouyang
Observed names:
Han-Yue OuYang,
Han‐Yue OuYang,
Han‐Yue Ouyang,
Han‑Yue Ouyang
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Boston Children's Hospital,
Harvard University,
Sun Yat-sen University,
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
ORCID:
0000-0003-3088-5228
Observed ORCID:
0000-0003-3088-5228
OpenAlex ID:
A5008468827
Genome‐wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth
2019
·
Yu Wang
, Bin Gao
, et al.
·
The FASEB Journal
·
89
PDF
Immunosuppressive Immature Myeloid Cell Generation Is Controlled by Glutamine Metabolism in Human Cancer
2019
·
Wen-Chao Wu
, Hong-Wei Sun
, et al.
·
Cancer Immunology Research
·
74
MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma
2015
·
Han‐Yue OuYang
, Jing Xu
, et al.
·
Hepatology
·
53
PDF
Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy
2018
·
Hai‐Long Chen
, Han‐Yue OuYang
, et al.
·
Cancer Medicine
·
48
PDF
Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma
2018
·
Min‑Ke He
, Yong Le
, et al.
·
Oncology Letters
·
37
PDF
Monomeric C-reactive protein regulates fibronectin mediated monocyte adhesion
2019
·
Naeem Ullah
, Fu-Rong Ma
, et al.
·
Molecular Immunology
·
29
Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
·
Clinical Cancer Research
·
24
Prognostic significance of sodium-potassium ATPase regulator, FXYD3, in human hepatocellular carcinoma
2017
·
Li‑Juan Wang
, Qi‑Jiong Li
, et al.
·
Oncology Letters
·
22
PDF
p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth
2020
·
Hanyue Ouyang
, Phi Luong
, et al.
·
Oncogene
·
18
PDF
p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP
2023
·
Hanyue Ouyang
, Shuang Wu
, et al.
·
Cell Reports
·
7
Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization
2016
·
Yong‐Fa Zhang
, Rong‐Ping Guo
, et al.
·
Liver International
·
2
Corrigendum to “Monomeric C-reactive protein regulates fibronectin mediated monocyte adhesion” [Mol. Immunol. 117 (2020) 122–130]
2020
·
Naeem Ullah
, Fu-Rong Ma
, et al.
·
Molecular Immunology
·
1
A scalable, high-throughput glue perturbation screening platform for molecular glue discovery
2026
·
Diyun Huang
, Zeyu Shuang
, et al.
·
iScience
Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First‐line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non‐comparative, Randomized Phase 2 Trial
2026
·
Zhicheng Lai
, Aojie Ge
, et al.
·
MedComm
Genome-Scale CRISPR Screens Reveal DNA Repair Dependencies That Sensitize Hepatocellular Carcinoma to Oxaliplatin
2026
·
Hanyue Ouyang
, Diyun Huang
, et al.
·
Cancers
PDF
Table S5 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S9 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S10 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S5 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S1 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S6 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S3 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S4 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S6 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Supplement 1 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Show more works
View as search
Works count:
48
Citation count:
404
H-index:
9
I10-index:
9
Year
Topic
Type